David A. Siegel Talaris Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.68 - $3.22 $372,860 - $447,988	139,127 Added 159.0%	226,627 $636,000
Q2 2023 Aug 14, 2023	BUY	$1.78 - $3.2 $110,360 - $198,400	62,000 Added 243.14%	87,500 $266,000
Q1 2023 May 15, 2023	SELL	$1.09 - $2.09 $8,938 - $17,138	-8,200 Reduced 24.33%	25,500 $47,000
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $31,678 - $55,268	33,700 New	33,700 $34,000
Q4 2021 Feb 14, 2022	SELL	$12.18 - $17.0 $138,852 - $193,800	-11,400 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.61 - $15.99 $135,837 - $187,083	-11,700 Reduced 50.65%	11,400 $155,000
Q2 2021 Aug 16, 2021	BUY	$12.25 - $18.61 $282,975 - $429,891	23,100 New	23,100 $339,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.